Ten63 Therapeutics just crossed the $45M mark, and if you understand the math behind molecules, you know that number is more than capital. It is conviction. Conviction that AI is not a buzzword in biotech. It is a weapon.
Let’s start where it matters. Marcel Frenkel, PhD, Co Founder and CEO, built this with Mark Hallen, PhD, and Bruce Donald, PhD. 3 Duke minds who decided the phrase “undruggable” sounded more like a dare than a diagnosis. Bruce Donald now chairs the Scientific Advisory Board, but make no mistake, the intellectual backbone runs through that original trio.
Back in May 2, 2023, Ten63 pulled in an oversubscribed $15.9M Series A led by Hatteras Venture Partners. Clay Thorp, Chairman of the Board and General Partner at Hatteras Venture Partners, leaned in. Morpheus Ventures, SOSV, Draper Associates, Alexandria Venture Investments, and the Sigma Group joined the table. When serious capital crowds into a round, it is rarely about hype. It is about signal.
Fast forward to February 19, 2026. Strategic financing. Total funding now over $45M. Chugai Venture Fund steps in. The Gates Foundation steps in. Mike Dial, PhD, Managing Director at Chugai Venture Fund, joins the board. Steve Hall, MD, PhD, serves as Independent Director. This is not random money. This is curated capital with a thesis.
The thesis is BEYOND. And the name is not subtle. This platform searches over 100 trillion synthetically feasible molecules. Not sketches on a whiteboard. Real chemical space. Ten63 blends generative AI with physics based models and quantum chemistry at scale. They are not asking AI to guess. They are forcing it to calculate.
This matters because oncology does not forgive guesswork. Resistance mutations show up like uninvited guests and overstay their welcome. The research lineage behind Ten63 pioneered predicting resistance before it walks into the clinic. That is not a feature. That is foresight. And now there is cervical cancer in the frame, backed by support tied to the Gates Foundation. Global impact is not a tagline. It is embedded in the capital stack.
Here is the quiet lesson. Ten63 did not raise on promises alone. They raised on deep science, institutional credibility, and a platform that marries generative AI with physics instead of pitting them against each other. The market rewards substance when it is undeniable.
For biotech founders watching from the sidelines, this is what leverage looks like. Academic rigor turned commercial engine. A board built with intent. Capital that aligns with mission. Ten63 is based in Durham, North Carolina, but the ambition is not regional. When you can search 100 trillion molecules, geography starts to feel small.
